Reduced expression of the functionally active complement receptor for iC3b but not for C3d on an avirulent mutant of Candida albicans. 1990

M W Ollert, and E Wadsworth, and R A Calderone
Department of Microbiology, Georgetown University Medical Center, Washington, D.C. 20007.

Pseudohyphae of Candida albicans bear surface receptors for iC3b and C3d. In order to determine a possible role for these receptors in the pathogenesis of candidiasis, a spontaneous C. albicans mutant, m-10, which exhibits reduced ability to adhere in vitro to fibrin platelet clots and epithelial cells or to cause endocarditis in a rabbit model, and its parent wild-type (wt) strain were compared for receptor expression in rosetting assays with sheep erythrocytes carrying iC3b (EAC1423bi) or C3d (EAC1423d). An equally high attachment to wt and m-10 was seen with EAC1423d, whereas rosetting with EAC1423bi was reduced by 53% in m-10 compared with wt. In inhibition studies, rosetting of wt with EAC1423bi was markedly inhibited by culture filtrate, hyphal-cell extract, and DEAE-fractionated material prepared from wt (54, 87, and 70% decreases in rosetting, respectively), thus suggesting the presence of the soluble, functionally active iC3b receptor of C. albicans in each of these preparations. Minimal inhibition of iC3b rosetting, however, was seen with the identical materials from m-10 (21, 5, and 12%, respectively). All of the preparations from the two strains were equally effective in their inhibitory activities against rosetting of C3d. A human serum specimen obtained from a patient with chronic mucocutaneous candidiasis blocked iC3b rosetting of the wt strain almost completely. When used in an immunoblot, this serum recognized proteins of 68 to 71, 55, and 50 kilodaltons (kDa) in hyphal-cell extracts of the wt. With the same preparation of the avirulent mutant, only weak reactions with the 68- to 71-kDa and 55-kDa proteins occurred, while the 50-kDa protein was not detectable. Taken together, these results indicate that the expression of the functionally active iC3b receptor on C. albicans may be involved in the virulence of the organism, possibly by mediating adherence to mammalian cells.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011951 Receptors, Complement Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement. Complement Receptors,Complement Receptor,Complement Receptor Type 1,Receptor, Complement
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D003179 Complement C3b The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g. C3b Complement,C3bi,Complement 3b,Complement Component 3b,Inactivated C3b,iC3b,C3b, Complement,C3b, Inactivated,Complement, C3b,Component 3b, Complement
D000944 Antigens, Differentiation, B-Lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin. Antigens, Differentiation, B-Cell,B-Cell Differentiation Antigens,B-Lymphocyte Differentiation Antigens,Blast-2 Antigen, B-Cell,Differentiation Antigens, B-Cell,Differentiation Antigens, B-Lymphocyte,Leu Antigens, B-Lymphocyte,Plasma Cell Antigens PC-1,Antigens, Differentiation, B Lymphocyte,Antigens, Plasma Cell, PC-1,B-Cell Blast-2 Antigen,Antigen, B-Cell Blast-2,Antigens, B-Cell Differentiation,Antigens, B-Lymphocyte Differentiation,Antigens, B-Lymphocyte Leu,B Cell Blast 2 Antigen,B Cell Differentiation Antigens,B Lymphocyte Differentiation Antigens,B-Lymphocyte Leu Antigens,Blast 2 Antigen, B Cell,Differentiation Antigens, B Cell,Differentiation Antigens, B Lymphocyte,Leu Antigens, B Lymphocyte,Plasma Cell Antigens PC 1
D014774 Virulence The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS. Pathogenicity
D015151 Immunoblotting Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies. Dot Immunoblotting,Electroimmunoblotting,Immunoelectroblotting,Reverse Immunoblotting,Immunoblotting, Dot,Immunoblotting, Reverse,Dot Immunoblottings,Electroimmunoblottings,Immunoblottings,Immunoblottings, Dot,Immunoblottings, Reverse,Immunoelectroblottings,Reverse Immunoblottings
D015933 Complement C3d A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001). C3d Complement,Complement 3d,Complement C3d Fragment,Complement Component 3d,C3d Fragment, Complement,C3d, Complement,Complement, C3d,Component 3d, Complement,Fragment, Complement C3d
D017463 Receptors, Complement 3b Molecular sites on or in some B-lymphocytes and macrophages that recognize and combine with COMPLEMENT C3B. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. Antigens, CD35,C3b Receptors,CD35 Antigens,CR1 Receptors,Complement 3b Receptors,Receptors, C3b,Receptors, CR1,CD 35 Antigens,CD35 Antigen,Complement 3b Receptor,Antigen, CD35,Antigens, CD 35,Receptor, Complement 3b
D017464 Receptors, Complement 3d Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognize and combine with COMPLEMENT C3D. Human complement receptor 2 (CR2) serves as a receptor for both C3dg and the gp350/220 glycoprotein of HERPESVIRUS 4, HUMAN, and binds the monoclonal antibody OKB7, which blocks binding of both ligands to the receptor. Antigens, CD21,C3d Receptors,CD21 Antigens,CR2 Receptors,Complement 3d Receptors,Complement Receptors 2,Epstein-Barr Virus Receptors,Receptors, C3d,Receptors, CR2,CD 21 Antigens,CD21 Antigen,Complement 3d Receptor,Complement Receptor 2,Epstein-Barr Virus Receptor,Herpesvirus 4 Receptors, Human,Receptors, Epstein-Barr Virus,Antigen, CD21,Antigens, CD 21,Epstein Barr Virus Receptor,Epstein Barr Virus Receptors,Receptor 2, Complement,Receptor, Complement 3d,Receptor, Epstein-Barr Virus,Receptors 2, Complement,Receptors, Epstein Barr Virus,Virus Receptor, Epstein-Barr,Virus Receptors, Epstein-Barr

Related Publications

M W Ollert, and E Wadsworth, and R A Calderone
November 1985, Infection and immunity,
M W Ollert, and E Wadsworth, and R A Calderone
June 1993, Infection and immunity,
M W Ollert, and E Wadsworth, and R A Calderone
January 1988, The Journal of infectious diseases,
M W Ollert, and E Wadsworth, and R A Calderone
April 1990, The Journal of infectious diseases,
M W Ollert, and E Wadsworth, and R A Calderone
February 2003, Medical mycology,
M W Ollert, and E Wadsworth, and R A Calderone
April 1993, Infection and immunity,
M W Ollert, and E Wadsworth, and R A Calderone
December 2008, Vaccine,
M W Ollert, and E Wadsworth, and R A Calderone
January 1988, Infection and immunity,
M W Ollert, and E Wadsworth, and R A Calderone
February 1989, Infection and immunity,
M W Ollert, and E Wadsworth, and R A Calderone
August 1988, Infection and immunity,
Copied contents to your clipboard!